Stockreport

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Soci...

Perspective Therapeutics, Inc.  (CATX) 
PDF [212Pb]VMT-a-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2.5 and 5.0 mCi)Eight of nine patients [Read more]